Alterations of HLA class i expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity

Cancer Immunology, Immunotherapy

Volumn 59, Issue 1, 2010, Pages 13-26

  Garrido, Cristina ^a,b   Algarra, Ignacio ^c   Maleno, Isabel ^a   Stefanski, Julia ^a   Collado, Antonia ^a   Garrido, Federico ^a,b   Garcia Lora, Angel M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

Author keywords

HLA alterations; Human tumor; Immunodeficient mice; Oncogenicity

Indexed keywords

GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; TUMOR IMMUNITY; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 70350107568     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0716-5     Document Type: Article

References (36)

1. I Algarra A García-Lora T Cabrera F Ruiz-Cabello F Garrido 2004 The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape Cancer Immunol Immunother 53 904 910 10.1007/s00262-004-0517-9 15069585 1:CAS:528:DC%2BD2cXntV2hsLo%3D (Pubitemid 39312657)
2. N Aptsiauri T Cabrera A Garcia-Lora MA Lopez-Nevot F Ruiz-Cabello F Garrido 2007 MHC class I antigens and immune surveillance in transformed cells Int Rev Cytol 256 139 189 10.1016/S0074-7696(07)56005-5 17241907 1:CAS:528:DC%2BD2sXmt1GksL0%3D (Pubitemid 46109029)
3. M Campoli S Ferrone 2008 HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance Oncogene 27 5869 5885 10.1038/onc.2008.273 18836468 1:CAS:528:DC%2BD1cXhtF2msbnF
4. GP Dunn LJ Old RD Schreiber 2004 The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 137 148 10.1016/j.immuni.2004. 07.017 15308095 1:CAS:528:DC%2BD2cXnsVKltrY%3D (Pubitemid 39094044)
5. GP Dunn LJ Old RD Schreiber 2004 The three Es of cancer immunoediting Annu Rev Immunol 22 329 360 10.1146/annurev.immunol.22.012703.104803 15032581 1:CAS:528:DC%2BD2cXktlOgs7k%3D (Pubitemid 38680426)
6. G Finak N Bertos F Pepin S Sadekova M Souleimanova H Zhao H Chen G Omeroglu S Meterissian A Omeroglu M Hallett M Park 2008 Stromal gene expression predicts clinical outcome in breast cancer Nat Med 14 518 527 10.1038/nm1764 18438415 1:CAS:528:DC%2BD1cXlsFCms7w%3D (Pubitemid 351655218)
7. FM Foss 2002 Immunologic mechanisms of antitumor activity Semin Oncol 29 5 11 10.1053/sonc.2002.33076 12068382 1:CAS:528:DC%2BD38Xltlaqtrs%3D
8. A Garcia-Lora I Algarra F Garrido 2003 MHC class I antigens, immune surveillance, and tumor immune escape J Cell Physiol 195 346 355 10.1002/jcp.10290 12704644 1:CAS:528:DC%2BD3sXjs1yhs7w%3D (Pubitemid 36529863)
9. A Garcia-Lora M Martinez I Algarra JJ Gaforio F Garrido 2003 MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated down-regulation of APM components Int J Cancer 106 521 527 10.1002/ijc.11241 12845647 1:CAS:528:DC%2BD3sXmtl2jsrg%3D (Pubitemid 36966208)
10. F Garrido T Cabrera A Concha S Glew F Ruiz-Cabello PL Stern 1993 Natural history of HLA expression during tumor development Immunol Today 14 491 499 10.1016/0167-5699(93)90264-L 8274189 1:CAS:528:DyaK2cXltFyktA%3D%3D (Pubitemid 23301000)
11. F Garrido F Ruiz-Cabello T Cabrera JJ Pérez-Villar M López-Botet M Duggan-Keen PL Stern 1997 Implications for immunosurveillance of altered HLA class I phenotypes in human tumors Immunol Today 18 89 95 10.1016/S0167-5699(96)10075-X 9057360 1:CAS:528: DyaK2sXhtlGqtbY%3D (Pubitemid 27107103)
12. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10.1016/S0092-8674(00)81683-9 10647931 1:CAS:528:DC%2BD3cXks1CktA%3D%3D
13. AN Khan CJ Gregorie TB Tomasi 2008 Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells Cancer Immunol Immunother 57 647 654 10.1007/s00262-007-0402-4 18046553 1:CAS:528:DC%2BD1cXitlKjsbs%3D
14. WJ Magner AL Kazim C Stewart MA Romano G Catalano C Grande N Keiser F Santaniello TB Tomasi 2000 Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors J Immunol 165 7017 7024 11120829 1:CAS:528:DC%2BD3cXovFygsrs%3D
15. I Maleno MA Lopez-Nevot T Cabrera J Salinero F Garrido 2002 Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 Cancer Immunol Immunother 51 389 396 10.1007/s00262-002- 0296-0 12192539 1:CAS:528:DC%2BD38Xnsl2gsLo%3D (Pubitemid 35002044)
16. J Manning M Indrova B Lubyova H Pribylova J Bieblova J Hejnar J Simova T Jandlova J Bubenik M Reinis 2008 Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumors Immunology 123 218 227 17725605 1:CAS:528:DC%2BD1cXhvF2htbo%3D
17. M Mareel A Leroy 2003 Clinical, cellular, and molecular aspects of cancer invasion Physiol Rev 83 337 376 12663862 1:CAS:528:DC%2BD3sXjtVagtr8%3D
18. R Méndez T Rodríguez A Del Campo E Monge I Maleno N Aptsiauri P Jiménez S Pedrinaci G Pawelec F Ruiz-Cabello F Garrido 2008 Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines Cancer Immunol Immunother 57 719 729 10.1007/s00262-007-0411-3 17934731 1:CAS:528:DC%2BD1cXitlKjtro%3D (Pubitemid 351641032)
19. D Nagorsen C Scheibenbogen FM Marincola A Letsch U Keilholz 2003 Natural T cell immunity against cancer Clin Cancer Res 9 4296 4303 14555498 1:CAS:528:DC%2BD3sXotVShsLw%3D
20. P Nisticò I Capone B Palermo D Del Bello V Ferraresi F Moschella E Aricò M Valentini L Bracci F Cognetti M Ciccarese G Vercillo M Roselli E Fossile ME Tosti E Wang F Marincola L Imberti C Catricalà PG Natali F Belardelli E Proietti 2009 Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients Int J Cancer 124 130 139 10.1002/ijc.23886 18839429 1:CAS:528:DC%2BD1cXhsFahtrnJ
21. H Norell M Carlsten T Ohlum KJ Malmberg G Masucci K Schedvins W Altermann D Handke D Atkins B Seliger R Kiessling 2006 Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity Cancer Res 66 6387 6394 10.1158/0008-5472.CAN-06-0029 16778217 1:CAS:528:DC%2BD28XlvVSku7g%3D
22. L Novellino C Castelli G Parmiani 2005 A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 187 207 10.1007/s00262-004-0560-6 15309328 1:CAS:528:DC%2BD2MXjs1ahug%3D%3D (Pubitemid 40174238)
23. L Paco AM Garcia-Lora C Casares C Cabrera I Algarra A Collado I Maleno F Garrido MA Lopez-Nevot 2007 Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response Int J Cancer 121 2023 2030 10.1002/ijc.22925 17621628 1:CAS:528:DC%2BD2sXhtFSjsLzM (Pubitemid 47463166)
24. G Pawelec SG Marsh 2006 ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank Cancer Immunol Immunother 55 623 627 10.1007/s00262-005-0117-3 16421722 1:CAS:528: DC%2BD28XhvFWqtLw%3D (Pubitemid 43312157)
25. LM Postovit NV Margaryan EA Seftor DA Kirschmann A Lipavsky WW Wheaton DE Abbott RE Seftor MJ Hendrix 2008 Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells Proc Natl Acad Sci USA 105 4329 4334 10.1073/pnas.0800467105 18334633 1:CAS:528: DC%2BD1cXktF2kur8%3D (Pubitemid 351754380)
26. T Rodriguez R Méndez CH Roberts F Ruiz-Cabello IA Dodi MA López Nevot L Paco I Maleno SG Marsh G Pawelec F Garrido 2005 High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity Cancer Immunol Immunother 54 141 148 10.1007/s00262-004-0561-5 15592718 1:CAS:528: DC%2BD2cXhtVGgt7fO (Pubitemid 40100836)
27. JM Romero P Jiménez T Cabrera JM Cózar S Pedrinaci M Tallada F Garrido F Ruiz-Cabello 2005 Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer Int J Cancer 113 605 610 10.1002/ijc.20499 15455355 1:CAS:528:DC%2BD2MXms1Gm (Pubitemid 40038737)
28. K Sabapathy SY Nam 2008 Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 function Cell Death Differ 15 1364 1374 10.1038/cdd.2008.55 18511935 1:CAS:528:DC%2BD1cXpvFKns7c%3D
29. EA Sausville AM Burger 2006 Contributions of human tumor xenografts to anticancer drug development Cancer Res 66 3351 3354 10.1158/0008-5472.CAN-05- 3627 16585151 1:CAS:528:DC%2BD28XjtVOksbc%3D
30. C Scheel T Onder A Karnoub RA Weinberg 2007 Adaptation versus selection: the origins of metastatic behavior Cancer Res 67 11476 11479 10.1158/0008-5472.CAN-07-1653 18089773 1:CAS:528:DC%2BD2sXhsVCjs7zL
31. T So M Takenoyama M Mizukami Y Ichiki M Sugaya T Hanagiri K Sugio K Yasumoto 2005 Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer Cancer Res 65 5945 5952 10.1158/0008-5472.CAN-04- 3787 15994973 1:CAS:528:DC%2BD2MXlslOqt7s%3D (Pubitemid 40911201)
32. JE Talmadge RK Singh IJ Fidler A Raz 2007 Murine models to evaluate novel and conventional therapeutic strategies for cancer Am J Pathol 170 793 804 10.2353/ajpath.2007.060929 17322365 1:CAS:528:DC%2BD2sXjs1Wls78%3D (Pubitemid 47339349)
33. TD Tisty LM Coussens 2006 Tumor stroma and regulation of cancer development Annu Rev Pathol 1 119 150 10.1146/annurev.pathol.1.110304.100224 1:CAS:528:DC%2BD28XktVOitb0%3D
34. A Villunger A Strasser 1999 The great escape: is immune evasion required for tumor progression? Nat Med 5 874 875 10.1038/11311 10426306 1:CAS:528:DyaK1MXltVyjsLk%3D (Pubitemid 29372409)
35. L Zitvogel L Apetoh F Ghiringhelli G Kroemer 2008 Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 59 73 10.1038/nri2216 18097448 1:CAS:528:DC%2BD2sXhsVKrsLnP
36. L Zitvogel L Apetoh F Ghiringhelli F André A Tesniere G Kroemer 2008 The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118 1991 2001 10.1172/JCI35180 18523649 1:CAS:528: DC%2BD1cXntVCmtr8%3D (Pubitemid 351872317)